Chimerix To Present At The Morgan Stanley Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, Chief Executive Officer of Chimerix, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m. ET at the Grand Hyatt Hotel in New York City.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at  http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates, including CMX669. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:Investor Relations: ir@chimerix.comorJesse BaumgartnerStern Investor RelationsJesse@sternir.com212-362-1200 Media:Becky VonsiatskyW2O Groupbvonsiatsky@w2ogroup.com413-478-2003

Primary Logo